The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Rather than creating a vaccine that mimics the RSV virus, they’re going straight to the source ... But an idiosyncrasy in ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

For adults aged 60 years or older, RSV vaccination is effective for preventing associated hospitalizations and ED encounters.

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

For a few years, the second seasonal COVID-19 spike has been accompanied by rising cases of seasonal flu and RSV in what health officials called ... fold increase in cases of pertussis in 2024, the ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

Do you know a “master of metamorphosis”? A scholar, some time ago, thus defined the influenza virus. Because it changes.

A research team at the University of Wisconsin-Madison produced high-resolution images of RSV structure, important for RSV ...